Hints and tips:
...The “windfall profits” drew fire from Elizabeth Warren, liberal Democratic senator, who called on the SEC to consider regulatory “reforms that would prevent abusive practices”....
...Rivals AstraZeneca, Johnson & Johnson, Russia’s Sputnik V and new entrants such as Novavax make up the remainder of the market, which is forecast to double in value to $124bn next year....
...An auction of two-year US Treasuries drew its strongest demand since April 2020, with the yield note falling 0.05 percentage points to 0.95 per cent....
...The AU will pay $6.75 a dose for the BioNTech/Pfizer vaccine and $10 for Johnson & Johnson’s, a single-dose product....
...The US and UK signed deals with BioNTech/Pfizer months earlier in July....
...Shares in Pfizer rose 7 per cent and chief executive Albert Bourla sold $5.6m of stock at a whisker from the company’s all-time high. This drew some negative attention....
...After such strong reads from the first two releases (three if we count Russia’s Sputnik V), the disappointing AZN figures were perhaps bound to prompt downward pressure on the company’s shares....
...In August, Russia became the first country to approve a Covid-19 vaccine — named Sputnik V — for civilian use, but western experts cast doubt on its efficacy and safety....
...A decade ago, Jeffrey Kindler, then chief executive of US drugs giant Pfizer, was plotting an audacious $68bn acquisition of rival Wyeth....
...Analyst James Wallick drew attention to a “excluded contributions” covenant: usually, these reflect the view that if shareholders contribute to a company's equity, they should be able to receive the amount...
...(NYT) News Round-up Private equity funds receive record amounts of capital (FT) China’s hobbled dealmakers yield foreign M&A crown to Japan Inc....
...It drew more eyeballs than the series finale of Seinfeld, and surpassed viewership for the past two Academy Awards shows combined....
...Comcast withdrew its $71bn takeover of Time Warner Cable last year, after the Department of Justice signalled it would try to stop the deal, which drew widespread opposition from campaigners who said it...
...Eric Schmidt, Google’s chairman, drew fire in 2013 when he defended the internet group’s tax affairs by pointing out that the company was merely working within the structure of the international tax regime...
...The largest deal seen in the sector, which requires US regulators’ approval, drew condemnation from politicians including Mrs Clinton, the frontrunner for the Democratic presidential nomination....
...The lesson many drew was not only that drug discovery was very expensive and hard — the US industry’s figure is that it costs an average of $2.6bn to bring a drug to market — but also that they were too...
...But none have been as big as the one thwarted by AstraZeneca’s board last May after a bitter battle that drew in politicians on both sides of the Atlantic and sparked debates over US tax policy and the UK...
...Last week’s USA v Germany match drew a record 1.7m concurrent streaming viewers to ESPN at its peak, with streaming on Univision peaking at 747,000....
...The highest profile example is GlaxoSmithKline, the UK pharmaceutical company, which last year centralised its intellectual property in Britain and drew up plans for its first new factory in Britain for...
...Meanwhile, Pfizer’s proposed takeover drew fresh criticism on Friday from Sweden, where AstraZeneca has 5,000 staff....
...The possibility of a Pfizer/AstraZeneca deal still has the politicians talking (the chief executives of both were hauled before the UK parliament this week)....
...Pfizer and Astra both drew on top names to advise them on communications strategy: their counsel came from two of the best-connected men in London, Sir Alan Parker and Roland Rudd....
...Potts, a leading company law advocate, drew attention to the famous case of Carlill v Carbolic Smoke Ball Company....
...Shire is the second FTSE 100 drugmaker to be subjected to an unsolicited takeover attempt by a US rival this year after Pfizer’s failed £69.4bn bid for AstraZeneca....
...However, while the latter approach drew strong political opposition because of AstraZeneca’s importance to the UK science base, the proposed Shire takeover has proved much less controversial....
International Edition